argenx NV ADR (ARGX)vsRoyalty Pharma Plc (RPRX)
ARGX
argenx NV ADR
$663.93
-3.01%
HEALTHCARE · Cap: $43.52B
RPRX
Royalty Pharma Plc
$45.36
-0.37%
HEALTHCARE · Cap: $26.53B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 79% more annual revenue ($4.25B vs $2.38B). RPRX leads profitability with a 32.4% profit margin vs 30.4%. ARGX appears more attractively valued with a PEG of 0.87. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
RPRX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-527.8%
Fair Value
$132.94
Current Price
$663.93
$530.99 premium
Margin of Safety
-17.3%
Fair Value
$37.74
Current Price
$45.36
$7.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 30 of every $100 in revenue as profit
Revenue surging 74.6% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 28.1%
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 32.0%
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.4% and operating margin at 28.1%. Revenue growth of 74.6% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while RPRX is a value play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
ARGX is growing revenue faster at 74.6% — sustainability is the question.
RPRX generates stronger free cash flow (827M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 61/100), backed by strong 30.4% margins and 74.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?